GMAB vs GMED
Genmab A/S vs Globus Medical — AI-powered side-by-side comparison
VS
GMED
Globus Medical
71
Buy
| Metric | GMAB | GMED |
|---|
| AI Score |
60
|
71
|
| Price |
$30.82
|
$85.12
|
| P/E Ratio |
24.04×
|
21.45×
|
| ROE |
16.5%
|
11.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
39.9%
|
68.5%
|
| Debt / Equity |
0.89×
|
0.02×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
72.5
|
75.9
|
| Beta |
0.685
|
0.954
|
| Expected Upside |
—
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for GMAB versus GMED.
GMED leads by 11 points.
GMED scores 71/100 (Buy) versus GMAB at 60/100 (Buy).
GMAB Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- EPS declining -25.3% YoY despite any revenue growth — Growth
- RSI at 73 is in overbought territory — Technical
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical